Home › Gurnet Point Capital Launches New Drug Development Company, Boston Pharmaceuticals, With $600M Commitment
 

Keywords :   


Gurnet Point Capital Launches New Drug Development Company, Boston Pharmaceuticals, With $600M Commitment

2015-11-20 04:25:37| drugdiscoveryonline Home Page

Gurnet Point Capital, an investment firm focused on the healthcare and life sciences sectors that was founded by Ernesto Bertarelli and is led by Christopher A. Viehbacher, recently announced the creation of Boston Pharmaceuticals, a fully-integrated drug development company that will offer an innovative alternative model for drug development and commercialization.

Tags: company point development capital

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
12.05Weekly Recap: Huggies Launches Skin Essentials Diaper, P&G Recognizes Key Suppliers & More
12.05California Bill Limits Skincare Sales to Teens & Persil Rebrands
12.05Kline Analysts Detail the Medical Dispensing Skin Care Market
12.05Glo30 Starts 2024 Strong with 60% Growth
12.05Zevo On-Body Repellent Teams with American Hiking Society To Provide Bug Bite Defense
12.05L\'Oréals Brand Value Soars to $13.4 Billion
12.05Spate Unveils the Top Sustainability Trends Cycling Google Searches
12.05Oh K! is the Most Searched Beauty Brand in the World: Cosmetify
More »